key: cord-0921109-b8zf1e65
authors: Farooq, Saba; Ngaini, Zainab
title: Natural and Synthetic Drugs as Potential Treatment for Coronavirus Disease 2019 (COVID-2019)
date: 2020-11-23
journal: Chemistry Africa
DOI: 10.1007/s42250-020-00203-x
sha: 1da2f254fa1b3865c76c38642953db5e67d0b11d
doc_id: 921109
cord_uid: b8zf1e65

Coronavirus disease 2019 (COVID-19) has become a global pandemic in a short period, where a tragically large number of human lives being lost. It is an infectious pandemic that recently infected more than two hundred countries in the world. Many potential treatments have been introduced, which are considered potent antiviral drugs and commonly reported as herbal or traditional and medicinal treatments. A variety of bioactive metabolites extracts from natural herbal have been reported for coronaviruses with some effective results. Food and Drug Administration (FDA) has approved numerous drugs to be introduced against COVID-19, which commercially available as antiviral drugs and vaccines. In this study, a comprehensive review is discussed on the potential antiviral remedies based on natural and synthetic drugs. This review highlighted the potential remedies of COVID-19 which successfully applied to patients with high cytopathic inhibition potency for cell-to-cell spread and replication of coronavirus.

The emergence of recent coronavirus disease 2019 (COVID-19) has become an alarming issue and shaken the whole world. The new pathogenic strain [1] produced by coronavirus has infected millions of people worldwide that led to massive death since December 2019 [2] . COVID-19 was first identified in Wuhan, China from an unknown source of coronavirus, which gradually spread to the whole world [3] [4] [5] [6] [7] and tragically affected human life. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19 in humans and animals [8] [9] [10] [11] [12] [13] [14] . COVID-19 has a similarity with the earlier reported disease called severe acute respiratory syndrome (SARS) caused by severe acute respiratory syndrome coronavirus (SARS-CoV), regarding their symptoms i.e. cough, fatigue, fever, and lower respiratory sign [15] [16] [17] . The current pandemic has compelled the researchers to explore new effective drugs against COVID-19.

SARS-CoV-2 is structurally similar to other coronavirus and is only differentiated by the prominent spike of proteins [18] . Coronaviruses belong to positive single-strand long RNA viruses [19, 20] with numerous structural proteins i.e. envelope (E), spike (S) [21] , membrane (M), nucleocapsid (N) proteins contributing or assisting virus for replication [22] and entry in the host [23] . Both SARS-CoV and SARS-CoV-2 have common angiotensin-converting enzyme 2 (ACE2) used as a receptor that is responsible for the respiratory syndrome. Startlingly, the spike-glycoprotein plays an important role for a strong guest host binding with the targets receptor [24] . The Mpro enzyme contributed to the viral replication of coronavirus [25] . The viral proteases (PL-pro and 3-CL pro) are contributed to the cleavage of replicate polyproteins, significant for viral replication [26] . SARS-CoV-2 can also enter into the host via endosomes at low pH, which can be controlled by increasing pH [27] . A comprehensive illustration of the SARS-CoV-2 structure, replication cycle and immune system response is depicted in (Fig. 1) [28, 29] .

The phylogenetic tree of coronaviruses consists of four types i.e. α-coronavirus, β-coronavirus, γ-coronavirus, δ-coronavirus [30] . Phylogeny and genomic analysis declared SARS-CoV-2 is belonged to β-coronavirus [ Coronavirus is mainly attacked on the respiratory system and also damages myocardial tissues [68, 69] and gastrointestinal organs [70] . Many common factors could seriously put patients at high risk such as (1) nature of drug/medicine, (2) dosage/potency of the drug, (3) condition of the patient (i.e. aging, obesity, sex [71] , diabetes, kidney illness [72, 73] , liver disease [74] , anxiety/ stress [75] , pregnancy [76] ). The existing connection between diabetes and obesity contributes to significant hazardous factors impacting the therapeutic severity of SARS-CoV-2 infections [77] . An ability to boost the body's immune system may significantly affect the medicinal remedies for COVID-19 treatment as a person to person immunity strength varies [78] . It equally affected young and old people. However, the affected ratio of females is lower compared to males due to a versatile hormonal system and immunity set up [79] .

Based on literature precedent, exhaustive efforts have been carried out to produce effective antiviral drugs to control coronavirus infection and replication [80, 81] in entry host and to enhance the host immune response [82, 83] might take several years before it's become commercially available. Many reviews [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] reported on the types, transmission or origin of coronavirus. In this review, natural and synthetic drugs-based treatments illustrated for COVID-19 and the outcomes of their drug's potential is thoroughly discussed.

Numerous treatment methods have been reported to cure COVID-19. Among various treatments, natural and synthetic remedies are the most commonly reported. Other strategies involved in the inactivation of pathogens especially on coronavirus infections have also been widely reported such as UV A [95] , UV C light [96] , heat sensitivity [97] octanoic acid treatment [98] , to name a few. The photodynamic and thermodynamic treatment strategies are involved penetration of UV light/heat into the fluid of platelet and inactivation of pathogenic microorganisms and leucocytes to damage the nucleic acids from continue spreading the viral.

The natural remedy is a naturally occurring secondary metabolite extracted from living organisms such as plants, animals, fungi and bacteria having potential antiviral agents [99] . The natural remedies are remarked as virtuous sources for the development and production of antiviral agents [100, 101] . Several metabolites derived from plants and animals have been recounted with antitumor, antifungal, antiinflammatory and antiviral properties [102, 103] . In Asian countries, herbal plant treatment has been conventionally used for many pharmaceutical purposes [104] .

Many studies reported on plants based natural products as alleged remedies for viral infection [105] . The bioactive metabolites from various parts of plant extract i.e. stems, seeds, roots and leaves have been widely reported with antiviral properties. Stephania tetrandra or Menispermaceae are examples of plants with excellent sources of bis-benzylisoquinoline alkaloids namely fangchinoline (1), tetrandrine (2) and cepharanthine (3). Compound (1-3) has been reported to inhibit protein expression, repress infectivity, and inhibit the replication of coronavirus in human and virus-induced host reappearance. Natural remedies from active metabolites (1-3) in the plant are beneficial and convenient for potential treatment and anticipation of COVID-19 (Fig. 2) [106] .

In Asia, conventional remedies based upon natural resources namely garlic, cardamom, pennyroyal, liquorice, pepper, turmeric, tragacanth and hedge nettle (Fig. 3 ) have been alleged for an effective cure against coronavirus diseases. Among these conventional remedies, curcumin, a secondary metabolite derived from turmeric, is more conspicuous and widely reported for potential COVID-19 treatment due to stronger interaction with protease enzyme as compared to other natural compounds (i.e. pepper, pennyroyal, tragacanth) [107] .

Chinese natural remedies have been renowned as imperative traditional remedies due to high efficiency, negligible and less side effects [108] . Chinese traditional herbs often offer rapid remedies for virus outbreak. Gancao (1), fangfeng (2), baizhu (3), jinyinhua (4) and huangqi (5) are examples of Chinese natural herbs that contain good antiviral potency with significant consequences (Fig. 4) [109, 110] . A commercial natural drug called Lianhua Qingwen is another Chinese herb derived from a combination of yinhuapinggan granule and San Wu huangqin decoction has been recently reported to cure COVID-19 in Beijing, China [111] .

Human or animal-derived remedies are significantly based upon the production of hormones, antibodies, secretion to the treatment of diseases. Plasma treatment is an example of specifically used remedies in the critical stage of COVID-19 treatment. 

Utilizing plasma from human blood who has recuperated from illness has been an alternative method to cure COVID-19. Plasma contains a natural antibody [112] which is helpful for the critical stage treatment known as plasma treatment of passive antibody therapy ( Fig. 5 ) [113] . Human 'sera' of convalescent patients (coronavirus disease recovered patients) cross neutralized SARS-CoV-2 S-driven entry [114, 115] . Convalescent plasma has successfully contributed to the COVID-19 recovery after the transfusion of plasma to bring the patient to the normal body temperature [116] . Plasma exchange therapy is an old treatment but found it helpful to fight for fatal COVID-19 [117] . Serological tests were recorded for confirmation of the efficiency of antibodies for coronavirus disease treatment via neutralization before the usage of plasma [118, 119] .

The spike protein is responsible for the formation of severe respiratory infection through the coronavirus by fusion or correlating with cellular receptors to target cells [120] . The ACE2 (angiotensin-converting enzyme 2) is a carboxypeptidase, which effectively terminates angiotensin II to angiotensin, has been recognized as a potent receptor for coronavirus. The recombinant protein achieved by the fusion of human extracellular domain ACE2 with the Fc section of human immunoglobulin IgG1 designated as ACE2-Ig contributed to the neutralization of spike protein [112] . The spike has a strong binding affinity with the receptor-binding domain (RBD) of coronaviruses and employs anticipated therapeutically properties [121] . In critical situations, plasma therapy is highly potential, more effective, easy to handle and safe for quick recovery of patients [122, 123] .

Microorganisms such as algae, fungi and bacteria have also contained bioactive compounds and used to treat coronavirus [124] . Metabolites from fungal contained reactive moieties for protease inhibitors against SARS-CoV-2. Taxol or paclitaxel are examples of active metabolites extracted from fungal species i.e. Pestlotia, Pithomyces and have been reported for coronavirus treatments due to anti-HIV activity [125] . Patel and his coworkers have explored the fungal metabolites i.e. quercitrin (G. triplex), bergenin (D. indusiata) and dihydroartemisinin (C. stercoreus) through computational studies, which shows potential remedies to inhibit the main protease of SARS-CoV-2 [126] .

Marine organisms are a well-known source for drug discovery in the therapeutic field [127] . Brown algae species such as Sargassum spinuligerum and Ecklonia cava has potential remedies against major protease protein of SARS-CoV-2 due to the presence of bioactive compounds 1,3,5-trihydroxybenzene and 8,8′-Bieckol, Dieckol, 6,6′-Bieckol [128, 129] . Moreover, microorganisms derived β-glucans can immune the body against coronavirus infections [130] .

Western-style methods to cure any disease is recognized as allopathic treatment [131] . In cases of pneumonia and positive coronavirus test, antiviral drugs are recommended to the patients, but in emergency cases, supplementary oxygen is highly suggested [132] [133] [134] . Due to quick spreading of COVID-19 crisis, previously reported antiviral, antimalarial or antiparasitic drugs (i.e. riboflavin [135] , lopinavir [136] , oseltamivir [137] , lopinavir/ritonavir [138] , minocycline [139] , tocilizumab [140] , ribavirin [141, 142] , niclosamide [143] , corticosteroids [144] , and ciclesonide [145] ) have been utilized for treatment. The clinical and laboratory trials are challenging to modern medicines [146] [147] [148] that is still under investigation. The promising outcomes of few drugs are illustrated below:

Ivermectin is a recognized Food and Drug Administration (FDA) approved antiparasitic drug [149] with potent antiviral activities [150] . Ivermectin, which previously reported to possess in vitro antiviral activity against a broad spectrum of coronaviruses [151, 152] 

Remdesivir (RDV) is another potential antiviral drug [154, 155] used to de-accelerate the RNA viral infections of SARS-CoV-2 ( Fig. 7) [156]. It was reported by Holshue et al. on the successful recovery of COVID-19 patients by using remdesivir. Nevertheless, treating severe coronavirus patients with remdesivir [157] has not shown good responses. A comparative analysis of various drugs i.e. remdesivir, ribavirin [158] , nitazoxanide, pencilovir, favipiravir, chloroquine and nafamostat has been comprehensively studied against COVID-19. The Vero E6 cells were infected with SARS-CoV-2 at a multiplicity of infection (MOI) of 0.05 and different concentrations of antiviral drugs for 48 h. The half-maximal effective concentration (EC 50 ) values and cytotoxicity percentage were evaluated by qRT-PCR and CCK-8 assays, respectively, which depicted all drugs have good inhibition activities. Interestingly, the low-micromolar concentration or less dosage of remdesivir is more effective to cure fatal corona disease [159] . There are instances that excess dosage could damage human organs especially on lung tissue [160] .

Chloroquine is another well-known autoimmune and antimalarial drug [161] . Chloroquine (Fig. 8) is a recognized drug to stop viral infection by enhancing the endosomal pH essential for the virus [162] , besides intrusive the glycosylation of coronavirus cellular receptors [163] . The addition of chloroquine in the infected sample exhibited antiviral activity against COVID-19. Chloroquine has an immunecontrolling activity, which interactively boosts up the in vivo antiviral effect. The drug is extensively reactive and distributed quickly to the whole body [159] . Essentially, the significance of chloroquine therapy is based upon age, stage of the disease and medicinal performance [164] .

Hydroxychloroquine (HCQ) (Fig. 9) [165] is a derivative of chloroquine and recently gazette as an authorized medicine for the treatment of corona disease [166] . A comparison of the properties of chloroquine and HCQ is depicted in Table 1 [163, 167, 168] . The severity of both HCQ and chloroquine can be reduced via assimilation with zinc supplement as zinc substance has been reported with a capability to reduce SARS-CoV-2 infection [169] .

A recent study has been reported on the effective dosage of HCQ that can inhibit viral infection detected via Web-PlotDigitizer (v4.2) software based on EC 50 . The observed EC 50 was 4.7 µM, which is comparable to the in vitro EC 50 's. The tremendous decrease in viral effect has been reported with HCQ doses > 400 mg twice in 1 day for ≥ 5 days against SARS-CoV-2 compared to the lower routine dose (≤ 400 mg daily). However, the HCQ > 600 mg dosage twice in 1 day was also effective. In contrast, the lower HCQ dose treatments may be insignificant to respond against the virus [170, 171] .

Incorporation of HCQ with azithromycin has produced synergistic repletion in viral infection as the azithromycin drugs able to increase the efficacy of the drugs [172] . Both drugs are cheap and commercially available [173] . Gautret et al. [174] have also reported on the efficiency of azithromycin incorporated with hydroxychloroquine and hydroxychloroquine for the treatment of COVID-19.

Hydroxychloroquine has recently become a controversial drug due to its discouraging results. WHO has suggestedbanning hydroxychloroquine to be used for COVID-19 treatment [175] due to the adverse effects on retina tissues, cardiac muscles, central nervous system and cause genotoxicity in DNA and liver cells [176] . Initial clinical results confirmed this drug has been found anti-SARS-CoV-2 effects both in vivo and in vitro and may have an effect on the treatment of coronavirus disease [177] . These unreliable experiences have also highlighted the misleading nature of controlled experimental trials.

Favipiravir or favilavir is an excellent antiviral [178] drug, traditionally known as Avigan and manufactured by Fujifilm [179] Toyama Chemical Company in Japan and China. Favipiravir has also been applied for coronavirus patients with improbability remains about drug effectiveness and safety [180] . However, this antiviral drug cause minor side effects [181] . The Favipiravir drug (Fig. 10) can be expressively inhibited viral clearance with a higher chest CT scan and depicted better improvement rates in moderate COVID-19 patients as compared to Lopinavir/Ritonavir [182] .

In summary, natural remedies are beneficial due to strong binding affinity, high efficacy and less side effects; whereas synthetic remedies are very reactive but indirectly may cause damage to other tissues or organs in the human body.

Despite several advantages have been reported on natural and synthetic remedies, the effectiveness of both remedies is mainly depending upon the condition of patients (i.e. mild, moderate, severe, critical) and the selection of medicinal protocol. The excessive dosage of synthetic remedies, however, is very hazardous as compared to natural remedies. Natural remedies gave more advantages and safer with limited drawbacks.

In searching for potential remedies of antiviral drugs, the production and discovery of antiviral agents from natural and synthetic sources have been intensively developed. The outcomes of these studies indicated that drugs derived from natural resources as bioactive antiviral compounds have more potential to cure coronavirus infection as compared to synthetic drugs with less side effects. Currently, clinical tests still ongoing on the suitable and effective medical treatment of COVID-19, which authentically supports the recovery chances of patient and toxicity of the drug, the effectiveness of drug synthesis to inhibit viral infection and the replication process. This review is particularly significant in the drug discovery process and exclusively describes the potential treatments by utilizing natural and synthetic drugs against coronavirus disease. 

A novel coronavirus from patients with pneumonia in China

Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach

First atypical case of 2019 novel coronavirus in Yan'an, China

The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus

Extracorporeal membrane oxygenation support in 2019 novel coronavirus disease: indications, timing, and implementation

The novel coronavirus originating in Wuhan, China: challenges for global health governance

Point-ofcare RNA-based diagnostic device for COVID-19

Overview of guidance for endoscopy during the coronavirus disease 2019 pandemic

Coronavirus disease (COVID-19) and neonate: what neonatologist need to know

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

COVID-19: combining antiviral and anti-inflammatory treatments

Expert recommendations for tracheal intubation in critically ill patients with noval coronavirus disease 2019

A distinct name is needed for the new coronavirus

Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides

Human saliva: non-invasive fluid for detecting novel coronavirus (2019-nCoV)

COVID-19: what has been learned and to be learned about the novel coronavirus disease

Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality

Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 task force

electrophysiology section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology

Putative natural history of CoViD-19

Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China

The novel coronavirus 2019 epidemic and kidneys

COVID-19 pneumonia in a hemodialysis patient

Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper

Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed

Pregnancy and perinatal outcomes of women with coronavirus disease (COVID-19) pneumonia: a preliminary analysis

Smartphone-based multiplex 30-minute nucleic acid test of live virus from nasal swab extract

Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay

Novel coronavirus disease (COVID-19): paving the road for rapid detection and point-of-care diagnostics

A review on coronavirus disease (COVID-19) epidemic threat for global health in 2020

Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

Development of antiviral therapy for severe acute respiratory syndrome

Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control

A comparative review of animal models of middle east respiratory syndrome coronavirus infection

A systematic review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

New and emerging infectious diseases (Ebola, Middle Eastern respiratory syndrome coronavirus, carbapenem-resistant Enterobacteriaceae, Candida auris): focus on environmental survival and germicide susceptibility

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review

Evolving status of the 2019 novel coronavirus infection: Proposal of conventional serologic assays for disease diagnosis and infection monitoring

Potential interventions for novel coronavirus in China: a systematic review

Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light

Inactivation of three emerging viruses-severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus-in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light

Heat sensitivity of a SARS-associated coronavirus introduced into plasma products

Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products

Antiviral drug discovery: broad-spectrum drugs from nature

Medicinal and therapeutic potential of herbs and plant metabolites/extracts countering viral pathogens-current knowledge and future prospects

Influenza neuraminidase: a druggable target for natural products

Antiviral natural products and herbal medicines

Identification of compounds from nigella sativa as new potential inhibitors of 2019 novel coronasvirus (Covid-19): molecular docking study

Tetrandrine-a molecule of wide bioactivity

Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective

Natural bis-benzylisoquinoline alkaloids-tetrandrine, fangchinoline, and cepharanthine, inhibit human coronavirus OC43 infection of MRC-5 human lung cells

2020) inhibitory effect of eight secondary metabolites from conventional medicinal plants on COVID_19 virus protease by molecular docking analysis

Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan

Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? a review of historical classics, research evidence and current prevention programs

Treatment of COVID-19: old tricks for new challenges

Traditional Chinese herbal medicine for treating novel coronavirus (COVID-19) pneumonia: protocol for a systematic review and meta-analysis

A human monoclonal antibody blocking SARS-CoV-2 infection

The convalescent sera option for containing COVID-19

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang

Convalescent plasma as a potential therapy for COVID-19

A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19

Convalescent plasma to treat COVID-19: possibilities and challenges

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Coronavirus disease 2019: what we know

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence

Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection

Virtual screening of natural products against type II transmembrane serine protease (TMPRSS2), the priming agent of coronavirus 2 (SARS-CoV-2)

Natural bioactive compounds from fungi as potential candidates for protease inhibitors and immunomodulators to apply for coronaviruses

Discovery of fungal metabolites bergenin, quercitrin and dihydroartemisinin as potential inhibitors against main protease of SARS-CoV-2

Pharmaceutical properties of marine polyphenols: an overview

Phytochemicals containing biologically active polyphenols as an effective agent against Covid-19-inducing coronavirus

Putative inhibitors of SARS-CoV-2 main protease from a library of marine natural products: a virtual screening and molecular modeling study

Purified β-glucans from the Shiitake mushroom ameliorates antibioticresistant Klebsiella pneumoniae-induced pulmonary sepsis

Allopathic medicine, profession, and capitalist ideology in India

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics

Design of the anti-HIV protease inhibitor darunavir. In: Introduction to biological and small molecule drug research and development

Coronavirus disease 2019: coronaviruses and blood safety

Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19

An algorithmic approach to diagnosis and treatment of coronavirus disease 2019 (COVID-19) in children: Iranian expert's consensus statement

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Minocycline superior to chloroquine phosphate as COVID-19 treatment

Update on treatment of COVID-19: ongoing studies between promising and disappointing results

novel coronavirus (COVID-19) outbreak: a review of the current literature

Drug repositioning in the treatment Of Covid-19

AI for the repurposing of approved or investigational drugs against COVID-19

Recent progress in the treatment of coronavirus disease

The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15

COVID-19 challenge for modern medicine

Race to find COVID-19 treatments accelerates

Effectiveness and safety of antiviral or antibody treatments for coronavirus

Molecular docking and molecular dynamic study of two viral proteins associated with SARS-CoV-2 with ivermectin. Preprints

Nsp7 and spike glycoprotein of SARS-CoV-2 are envisaged as potential targets of vitamin D and ivermectin. Preprints

Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus

The importin α/βspecific inhibitor ivermectin affects HIF-dependent hypoxia response pathways

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

COVID-19 docking server: an interactive server for docking small molecules, peptides and antibodies against potential targets of

novel coronavirus-important information for clinicians

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

First case of 2019 novel coronavirus in the United States

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Emerging pharmacotherapies for COVID-19

Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine

Of chloroquine and COVID-19

Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease

An overview of novel corona virus 2019-nCoV and their clinical and immune responses

Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19

Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal

Improving the efficacy of chloroquine and hydroxychloroquine against SARS-CoV-2 may require zinc additives-a better synergy for future COVID-19 clinical trials

Optimizing hydroxychloroquine dosing for patients with COVID-19: an integrative modeling approach for effective drug repurposing

Hydroxychloroquine; why it might be successful and why it might not be successful in the treatment of Covid-19 pneumonia? Could it be a prophylactic drug? Preprints

In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Hydroxychloroquine, dermatology, and SARS-CoV-2: updating an old association

Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review

Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19

Computational lead discovery for COVID-19 recovery. Favilavir isostere analog as promising remedy of corona viral infection

Kinetic analysis and fragment screening with Fujifilm AP-3000

Favipiravir for treating novel coronavirus (COVID-19) patients: protocol for a systematic review and meta-analysis of controlled trials

Coronavirus (COVID-19): history, current knowledge and pipeline medications

Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: a pilot retrospective study

The authors would like to thank The Ministry of